Summary of PHARMAC decisions

EFFECTIVE 1 December 2020

New listings 

  • Calcium carbonate (Calci-Tab 500) tab 1.25 g (500 mg elemental)
  • Emicizumab (Hemlibra) inj 30 mg in 1 ml vial, 60 mg in 0.4 ml vial, 105 mg in 0.7 ml vial and 150 mg in 1 ml vial – Xpharm and Special Authority
  • Potassium chloride (Juno) inj 75 mg per ml, 10 ml – S29 and wastage claimable
  • Pimecrolimus (Elidel) crm 1%, 15 g OP – Special Authority – Retail pharmacy
  • Pregnancy test – HCG urine (David One Step Cassette Pregnancy Test) cassette, 40 test OP – up to 200 test available on a PSO and only on a PSO
  • Carbimazole (Neo-Mercazole S29) tab 5 mg – S29 and wastage claimable
  • Goserelin (Teva) implant 3.6 mg, syringe and implant 10.8 mg, syringe
  • Tobramycin (Tobramycin BNM) solution for inhalation 60 mg per ml, 5 ml – subsidy by endorsement and wastage claimable
  • Neostigmine metilsulfate (Max Health) inj 2.5 mg per ml, 1 ml ampoule
  • Cyclizine lactate (Hameln) inj 50 mg per ml, 1 ml
  • Melphalan (Alkeran S29) inj 50 mg – PCT only – Specialist and S29
  • Mitomycin C (Teva) inj 20 mg vial – PCT only – Specialist
  • Imatinib mesilate (Imatinib-Rex) cap 400 mg
  • Travoprost (Mylan) eye drops 0.004%, 5 ml OP – S29
  • Pharmacy services (BSF Atomoxetine Generic Partners) brand switch fee – may only be claimed once per patient
  • Aminoacid formula without phenylalanine (PKU Anamix Infant) infant formula, 400 g OP – Special Authority – Hospital pharmacy [HP3]

Changes to restrictions

  • Hydroxocobalamin (Hydroxocobalamin Mercury Pharma) inj 1 mg per ml, 1 ml ampoule – S29 and wastage removed
  • Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe – amended Special Authority criteria
  • Escitalopram (Escitalopram-Apotex) tab 10 mg and 20 mg – reinstate stat dispensing
  • Moclobemide (Aurorix) tab 300 mg – remove stat dispensing
  • Pregabalin (Lyrica) cap 150 mg – S29 and wastage removed
  • Sumatriptan (Imigran) inj 12 mg per ml, 0.5 ml prefilled pen – brand switch fee removed
  • Prochlorperazine (Nausafix) tab 5 mg – reinstate stat dispensing
  • Atomoxetine (Generic Partners) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg – addition of brand switch fee
  • Pegaspargase (Oncastar LYO) inj 750 iu per ml, 5 ml vial – amended Special Authority criteria
  • Etanercept (Enbrel) inj 25 mg, inj 50 mg autoinjector and prefilled syringe – amended Special Authority criteria
  • Adalimumab inj 20 mg per 0.4 ml and 40 mg per 0.8 ml prefilled syringe (Humira) and inj 40 mg per 0.8 ml prefilled pen (HumiraPen) – amended Special Authority criteria
  • Rituximab inj 100 mg per 10 ml and 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter (Mabthera)) – amended Special Authority criteria
  • Tocilizumab inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial (Actemra) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Dornase alfa (Pulmozyme) nebuliser soln, 2.5 mg per 2.5 ml ampoule – amended Special Authority criteria
  • Extensively hydrolysed formula (Aptamil AllerPro SYNEO 1 and Aptamil AllerPro SYNEO 2) – amended brand name

Increased subsidy 

  • Mitomycin C (Baxter) inj 1 mg for ECP

Increased price but not subsidy 

  • Mupirocin (Bactroban) oint 2%, 15 g OP
  • Clobetasone butyrate (Eumovate) crm 0.05%, 30 g OP